company presentation - flanders investment & trade
TRANSCRIPT
COMPANY PRESENTATION
February 2016
NASDAQ: KMDA
Fully integrated, international (NASDAQ-traded) biopharmaceutical company
Diversified portfolio with over 20 specialty products.
Focused on Respiratory, orphan diseases and plasma derived therapeutics
Global leader for Alpha-1 Antitrypsin (AAT)
Exclusive distributer of leading biopharmaceutical companies with significant market share ( > 50%).
Strategic partnerships with industry leaders (Inc. Baxalta, Biotest, Kedrion, Chiesi)
Company Snapshot
Mission
3
Development, production and marketing
of specialty, life-saving pharmaceuticals
Unique Product Line
Strategic Partnerships
Significant Market Share
Strategy
Media Coverage
4
Kamada and Baxter Enter into a Strategic Agreement for the Distribution and Manufacture of Intravenous Liquid AAT to Treat Alpha-1 Antitrypsin Deficiency in the US
24 Aug. 2010
Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its human Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease
2 Feb. 2015
Kamada Reports Encouraging Interim Data from its Phase 1/2 Extension Study: AAT in pediatric patients with Type 1 Diabetes
Bloomberg
11 Dec. 2014
Kamada Ltd Announces New Exclusive Distribution Agreement with Chiesi Farmaceutici
4 Aug. 2012
NASDAQ Welcomes Kamada Ltd. [KMDA] to The NASDAQ Stock Market
31 May. 2013
Kamada Announces Completion of Pivotal Phase ll/lll Clinical Trial in Europe and Canada of inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency
11 Dec. 2013
Multi-National Sales Platform
5
Additional 10 countries in registration
Key Strategic Alliances
Diversified Product Portfolio
7
RESPIRATORY
ANTIBODIES (various expertise)
Anti-rabies immunoglobulin (human) Rho(D) immunoglobulin (human) Rho(D) immunoglobulin (human) Gamma globulins (IgG) (human) Varicella zoster immunoglobulin Hepatitis B immunoglobulin (human) Hepatitis B immunoglobulin (human) CMV immunoglobulin (human) Anti-snake venom CRITICAL AND
HOSPITAL CARE
Heparin sodium 5,000 IU/ml Human serum Albumin Heparin sodium Bupivacaine HCl
HAEMOPHILIA Coagulation Factor VIII (human) Coagulation Factor IX (human)
Alpha-1 Antitrypsin I.V (human) Tobramycin Inhaled Beclomethasone+Formoterol
Clinical Pipeline Focused on Orphan Indications
Product Indication Phase I Phase II Phase III Market Partner
Intravenous
AAT AAT Deficiency U.S.
D1-AAT (IV) Type 1 Diabetes* U.S.
G1-AAT (IV) GVHD* U.S.
L1-AAT (IV) Lung Transplant U.S.
Inhaled AAT AAT Deficiency*
B1-AAT (IH) Bronchiectasis*
C1-AAT (IH) Cystic Fibrosis*
KamRAB (IM) Prophylaxis for
Rabies U.S. U.S: Phase III Completed (LPO)
Ph II/III In Process
FDA Approved (2010)
Completed
Ph I/II In Process
U.S.: IND
Approved
U.S.: Ph II In Process
EU: Completed
Completed
Completed
* Orphan Drug Designation IV= intravenous IH= inhaled
Ph I/II in Initiation
EU
cGMP standard, one stop shop:
registration, regulation support, importation,
distribution, storage, marketing, pharmacovigilance,
clinical trials and QA, QC.
Long term experience in development and
marketing of specialty Rx pharmaceuticals.
Excellent relationships with key personnel at the
Israeli MOH and HMOs (management, decision
makers, medical department and purchase
department).
Our Israeli Sales & Marketing Strengths & Capabilities
9
Vast experience in various medical fields: Respiratory,
Allergy & Immunology, Hematology, Infectious diseases,
Neurology, Critical care, Gastroenterology & Liver
diseases, Fertility and more.
Proven multinational sales capabilities through long-term
connection with local distributors in Latin America, CIS &
Asia.
FDA approved, State of the art production facility.
More than 50% market share in key in-licensed products.
Kamada’s success and market share growth is achieved through
a collaboration with KOLs and the establishment of a leading premium brand.
• A seasoned team of medical reps covering all hospitals and most primary-care clinics.
• On going personal contact with KOLs and physicians.
• Local adaptations of all marketing aids: leaflets, brochures, scientific articles, etc.
• Sponsorship of relevant medical conferences & seminars.
• Strong marketing intelligence capabilities.
• Advanced digital marketing capabilities.
• In-house medical director support.
Dedicated to Create a Leading Brand
10
Market research & analysis, including
detailed business plan.
Expertise in Market Development of Orphan Indications
11
Raising disease awareness & patients diagnosis,
through effective diagnosis programs.
Collaboration with KOLs and dedicated
treatment centers.
Patients and physicians organizations
support, Development of patients
support programs.
Experience in Named-Patient-Basis
sales, prior to registration.
• Regulatory Capabilities:
o In-house, experienced dedicated regulatory affairs department.
o Proven record in submission and approvals to the National health basket.
o Pharmacovigilance (in cooperation with QA and Clinical).
• Logistic Capabilities:
o In-house storage (fully cGMP and FDA approved).
o Extensive cold-chain expertise.
o Advanced nation-wide cGDP-approved delivery platform.
o Home care experience and capabilities.
o Dedicated account management & customer service.
One-Stop-Shop Services
12
• The national leader in logistics for the pharmaceutical industry, with Cutting edge facility
for the storage and distribution of pharmaceutical products
• Serves more than 1,200 delivery points throughout Israel
• Immediate life saving deliveries 24/7
Novolog: Our Logistic Partner
13
14
A one- stop- shop strategic
partner
In-house seasoned sales & marketing
team
Multinational capabilities and strong financial
positioning
Unique expertise through the entire
supply chain of specialty life- saving
pharmaceuticals
Why Partner with Kamada
